Isatuximab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Isatuximab |
| DrugBank ID | DB14811 |
| Brand Names (EU) | Sarclisa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.23% |
Approved Indication (EMA)
SARCLISA is indicated: In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In combination with b
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | indolent plasma cell myeloma | 98.23% | DL |
| 2 | plasma cell myeloma | 97.58% | DL |
| 3 | cholangiocarcinoma, susceptibility to | 65.08% | DL |
| 4 | minimally invasive lung adenocarcinoma | 63.55% | DL |
| 5 | placenta disease | 62.84% | DL |
| 6 | GCGR-related hyperglucagonemia | 61.80% | DL |
| 7 | hemoglobin C-beta-thalassemia syndrome | 61.50% | DL |
| 8 | giant cell reparative granuloma | 59.41% | DL |
| 9 | dental caries | 58.71% | DL |
| 10 | colon inflammatory polyp | 58.71% | DL |
| 11 | epidural abscess | 58.05% | DL |
| 12 | prostate adenoid cystic carcinoma | 57.92% | DL |
| 13 | acute articular rheumatism | 57.55% | DL |
| 14 | cloacogenic carcinoma | 57.53% | DL |
| 15 | conduct disorder | 57.46% | DL |
| 16 | intraductal tubulopapillary neoplasm of pancreas | 57.36% | DL |
| 17 | renal artery obstruction | 57.22% | DL |
| 18 | mitral valve stenosis | 57.18% | DL |
| 19 | Coronavinae infectious disease | 57.13% | DL |
| 20 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 57.13% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.